This clinical trial is focused on studying the long-term safety of a treatment called isatuximab for patients with multiple myeloma, a type of cancer that affects plasma cells in the bone marrow. The study is designed for patients who have previously participated in earlier phases of research involving isatuximab and have experienced benefits from the treatment. The main goal is to continue monitoring the safety of isatuximab when used alone or in combination with other treatments.

Participants in this study will continue to receive isatuximab as they did in their previous study. The treatment will be administered either as a single therapy or alongside other medications, depending on what was used in the earlier study. The study will track any new side effects or health issues that arise during the treatment period. This will help researchers understand the long-term effects of isatuximab and ensure it remains safe for patients who continue to benefit from it.

The study will last for several years, allowing researchers to gather comprehensive data on the safety of isatuximab over an extended period. This information is crucial for determining the best ways to use isatuximab in treating multiple myeloma and ensuring that patients receive the most effective and safe care possible. Participants will be closely monitored by their healthcare providers throughout the study to ensure their well-being and to address any concerns that may arise during the treatment.